The addition of bortezomib to a standard two-drug regimen for myeloma patients significantly lengthened the time before their cancer returned, and significantly lengthened their lives, according to new SWOG clinical trial results presented at the 57th Annual Meeting of the American Society of Hematology (ASH) held in Orlando, Florida.
As part of a major effort to expand access to cancer clinical trials for the nationís military veterans, SWOG and its charitable arm, The Hope Foundation, are providing $125,000 to five U.S. Department of Veterans Affairs medical centers across the country.
Accrual barriers to S1314 COXEN Trial lowered
[Jul. 8, 2015]
The S1314 COXEN trial for pre-operative bladder cancer patients has been amended to reduce barriers to activation and enrollment. Please reconsider the study at your site.
Based on SWOG member feedback, we have:
Removed the requirement that urologists must have performed at least 50 cystectomies in the last 3 years to participate in COXEN.
Removed the requirement that tissue blocks be submitted; instead, institutions now can send tissue slides.
Widened the allowable window for screening tests, clarified urine sample processing, and increased latitude for chemotherapy administration.
The COXEN neoadjuvant bladder study (S1314) is testing whether the COXEN gene expression model can predict the best chemotherapy treatment for patients based on individual tumor characteristics. This protocol randomizes T2-T4aN0M0 bladder cancer patients preoperatively to Gem-Cis versus MVAC chemotherapy. The primary endpoint is the pT0 rate, and trial investigators will examine the COXEN prognostic and predictive performance in this regard.
The COXEN trial will enroll 184 bladder cancer patients planning for cystectomy. If your institution has not opened S1314, please consider this study in light of these amendment changes. For questions, contact S1314 Principal Investigator Dr. Thomas Flaig at Thomas.Flaig@ucdcenver.edu or (303) 724-0499.